Immunity after Yellow Fever vaccination - YETI research
Research type
Research Study
Full title
Immunity after yellow fever vaccination in travelers using immunosuppressive medication and HIV positive patients-YETI study
IRAS ID
128476
Contact name
David Dockrell
Contact email
Sponsor organisation
Academic Medical Centre
Research summary
Yellow Fever vaccination (YFV) is a live attenuated vaccine, meaning it contains a weakened version of the yellow fever virus. It is safe and very effective in healthy individuals, but there are concerns that in those with weakened immune systems (such as individuals with HIV infection), the YFV may be less effective and potentially result in a higher risk of side effects. Yet it is still given to immunosuppressed individuals where the risk of acquiring Yellow Fever is felt to be higher than the risk of side effects from the vaccine. Few studies have explored how good the immune system’s response to YFV is in immunosuppressed individuals.
This study proposes to recruit individuals taking immunosuppressive medication, as well as individuals with HIV infection, who have received YFV within the last 20 years and compare their immune responses to YFV to healthy controls. Participants will also be asked to fill in a questionnaire to assess any side effects experienced following vaccination.REC name
London - Camberwell St Giles Research Ethics Committee
REC reference
14/LO/0241
Date of REC Opinion
3 Apr 2014
REC opinion
Further Information Favourable Opinion